Analyst: Novo case is a matter of principle
The Danish FSA’s decision to report Novo Nordisk to the police looks mostly like a matter of principle, says an analyst. He does not expect the role of the management to be an issue in the case.
by Benjamin Werner Christensen
It is mostly a great case for the press. From the point of view of the market, the Danish FSA’s decision to report Novo Nordisk to the police - citing a violation on the part of the company to disclose internal information as soon as possible following the FDA’s rejection of insulin products Tresiba and Ryzodeg – is mostly a matter of principle, says Michael Friis Jørgensen, analyst in Alm. Brand Markets.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo: We didn’t have the full grasp until Sunday
For abonnenter
Novo reported to the police by Danish FSA
For abonnenter
